Billiontoone, Inc. (NASDAQ:BLLN – Get Free Report) CEO Oguzhan Atay sold 12,500 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $126.10, for a total transaction of $1,576,250.00. Following the completion of the transaction, the chief executive officer directly owned 12,500 shares of the company’s stock, valued at approximately $1,576,250. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Oguzhan Atay also recently made the following trade(s):
- On Monday, July 6th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total transaction of $1,525,625.00.
- On Monday, July 6th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The stock was sold at an average price of $122.05, for a total transaction of $3,203,812.50.
- On Monday, June 8th, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total value of $1,227,750.00.
- On Monday, June 8th, Oguzhan Atay sold 26,250 shares of Billiontoone stock. The shares were sold at an average price of $97.66, for a total value of $2,563,575.00.
Billiontoone Stock Performance
BLLN opened at $123.25 on Tuesday. Billiontoone, Inc. has a 52-week low of $61.96 and a 52-week high of $138.70. The firm has a market capitalization of $5.67 billion and a PE ratio of 224.09. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The business’s 50-day simple moving average is $101.46 and its 200 day simple moving average is $89.09.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Adams Street Partners LLC acquired a new position in shares of Billiontoone during the 4th quarter worth approximately $140,063,000. Baillie Gifford & Co. acquired a new stake in Billiontoone during the 4th quarter valued at $103,786,000. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the fourth quarter worth $39,717,000. JPMorgan Chase & Co. bought a new position in Billiontoone during the fourth quarter worth $32,078,000. Finally, Wasatch Advisors LP acquired a new position in shares of Billiontoone in the first quarter valued at $29,179,000.
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on the stock. BTIG Research decreased their target price on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Guggenheim assumed coverage on shares of Billiontoone in a research note on Monday, June 29th. They issued a “buy” rating and a $125.00 price target for the company. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Billiontoone has an average rating of “Moderate Buy” and a consensus target price of $126.00.
Read Our Latest Stock Analysis on BLLN
About Billiontoone
BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.
BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.
Read More
- Five stocks we like better than Billiontoone
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Billiontoone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Billiontoone and related companies with MarketBeat.com's FREE daily email newsletter.
